Sugi Predict

Sugi Predict / Compounds / SCHEMBL526496

SCHEMBL526496

SCHEMBL526496

Nc1cc(-c2ccccc2)c(Cl)nn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 2/20 0.46
▸ SMARCA4 P51532 2/20 0.46
▸ PBRM1 Q86U86 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MEN1 O00255 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CYP2A6 P11509 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16092209 0.82 MAPT (0.44) ALDH1A1HSD17B10MEN1KMT2ACASP1
SCHEMBL1752831 0.79 SMARCA2 (0.59) SMARCA2SMARCA4PBRM1ALDH1A1HSD17B10
SCHEMBL30041839 0.79 CYP2A6 (0.43) SMARCA2SMARCA4PBRM1ALDH1A1MEN1
SCHEMBL527009 0.79 CYP2A6 (0.43) SMARCA2SMARCA4PBRM1ALDH1A1MEN1
SCHEMBL15761411 0.78 ADORA2A (0.48) SMARCA2SMARCA4PBRM1ALDH1A1HSD17B10
SCHEMBL1038525 0.77 CASP1 (0.48) MAP4K4CASP1NPC1RAB9A
SCHEMBL28685605 0.77 CASP1 (0.48) ALDH1A1HSD17B10KMT2ACASP1KDM4E
SCHEMBL1754675 0.76 KDM4E (0.44) SMARCA2SMARCA4PBRM1ALDH1A1HSD17B10
SCHEMBL19813305 0.74 CYP2A6 (0.44) ALDH1A1CYP2A6TDO2
SCHEMBL1754688 0.72 MAPK1 (0.53) SMARCA2SMARCA4PBRM1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4269409-A1 AMIDE OXAZOLE COMPOUND Medshine Discovery Inc. (CN) 2023-11-01 — — EP disclosed
US-20210070708-A1 Pharmaceutically Active Compounds BERGENBIO ASA (NO) 2021-03-11 — — US disclosed
US-10766861-B2 Pharmaceutically active compounds BERGENBIO ASA (NO) 2020-09-08 — — US disclosed
CN-107207472-B Inhibitors of AKT kinase 卑尔根生物股份公司 2020-08-14 — — CN disclosed
US-10336702-B2 Pharmaceutically active compounds BERGENBIO ASA (NO) 2019-07-02 — — US disclosed
US-20180029985-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS BERGENBIO AS (NO) 2018-02-01 — — US disclosed
EP-3240784-A2 INHIBITORS OF AKT KINASE BerGenBio ASA (NO) 2017-11-08 — — EP disclosed
US-9730929-B2 Substituted aminoimidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-08-15 — — US disclosed
EP-2714692-B1 SUBSTITUTED AMINOIMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2017-03-22 — — EP disclosed
CN-103814029-B Substituted imidazopyridazines 拜耳知识产权有限责任公司 2016-10-12 — — CN disclosed
US-20100204212-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 — — US disclosed
US-7723336-B2 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-25 — — US disclosed
CN-101312977-A Fused heterocyclic compounds useful as kinase modulators BRISTOL MYERS SQUIBB CO (US) 2008-11-26 — — CN disclosed
EP-1928879-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS Brystol-Myers Squibb Company (US) 2008-06-11 — — EP disclosed
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US disclosed
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 — — EP disclosed
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 — — US disclosed
WO-2007038314-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-05 — — WO disclosed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 — — WO disclosed
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators MAP3K2, MAP3K3, MAP4K2 SMARCA2 2069/4885SMARCA4 2325/4885PBRM1 1926/4885
US-10336702-B2 Pharmaceutically active compounds UGT2B7, CYP3A5, UGT1A1 SMARCA2 3316/4885SMARCA4 2750/4885PBRM1 2751/4885
US-20100204212-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS MAP2K2, MAP3K2, MAP4K2 SMARCA2 1748/4885SMARCA4 2523/4885PBRM1 1609/4885
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP SMARCA2 2407/4885SMARCA4 2228/4885PBRM1 3696/4885
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS MAP3K3, MAP3K2, MAP4K3 SMARCA2 1758/4885SMARCA4 2241/4885PBRM1 1538/4885
US-20210070708-A1 Pharmaceutically Active Compounds UGT2B7, CYP3A5, UGT1A1 SMARCA2 3364/4885SMARCA4 2811/4885PBRM1 2686/4885
US-10766861-B2 Pharmaceutically active compounds UGT2B7, CYP3A5, UGT1A1 SMARCA2 3364/4885SMARCA4 2811/4885PBRM1 2686/4885
US-20180029985-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS UGT2B7, CYP3A5, UGT1A1 SMARCA2 3316/4885SMARCA4 2750/4885PBRM1 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.